Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tyvaso
Pharma
FDA balks at standard nod to Liquidia's PAH rival to United med
The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia in FDA limbo until 2025.
Zoey Becker
Aug 19, 2024 11:34am
Courts clear FDA to approve Liquidia's PAH drug Yutrepia
Apr 2, 2024 9:33am
FDA faces lawsuit from United on its Liquidia review process
Feb 21, 2024 2:31pm
United Therapeutics lands blow in inhaled drug patent dispute
Sep 1, 2022 12:17pm
United scores hard-earned FDA approval for inhaled Tyvaso
May 24, 2022 9:38am
Lung safety review delays FDA decision on United's Tyvaso DPI
Mar 1, 2022 10:01am